Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Federal Trade Commission
Covington
Mallinckrodt
Medtronic
US Army
Harvard Business School
McKesson
Baxter

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020762

« Back to Dashboard

NDA 020762 describes NASONEX, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from four suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the NASONEX profile page.

The generic ingredient in NASONEX is mometasone furoate. There are twenty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for 020762
Tradename:NASONEX
Applicant:Merck Sharp Dohme
Ingredient:mometasone furoate
Patents:1
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Formulation / Manufacturing:see details
Pharmacology for NDA: 020762
Medical Subject Heading (MeSH) Categories for 020762
Suppliers and Packaging for NDA: 020762
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NASONEX mometasone furoate SPRAY, METERED;NASAL 020762 NDA Merck Sharp & Dohme Corp. 0085-1288 N 0085-1288-03
NASONEX mometasone furoate SPRAY, METERED;NASAL 020762 NDA Merck Sharp & Dohme Corp. 0085-1288 N 0085-1288-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrengthEQ 0.05MG BASE/SPRAY
Approval Date:Oct 1, 1997TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Apr 3, 2018Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 020762

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Mallinckrodt
Boehringer Ingelheim
Federal Trade Commission
Citi
Harvard Business School
Fish and Richardson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot